{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:34:18Z","timestamp":1789616058496,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T00:00:00Z","timestamp":1305158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s12031-011-9539-x","type":"journal-article","created":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T07:44:56Z","timestamp":1305099896000},"page":"145-152","source":"Crossref","is-referenced-by-count":16,"title":["Changes in the mRNA Levels of \u03b12A and \u03b12C Adrenergic Receptors in Rat Models of Parkinson\u2019s Disease and l-DOPA-Induced Dyskinesia"],"prefix":"10.1007","volume":"46","author":[{"given":"Amal","family":"Alachkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,12]]},"reference":[{"issue":"3","key":"9539_CR1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neures.2010.03.008","volume":"67","author":"A Alachkar","year":"2010","unstructured":"Alachkar A, Brotchie JM, Jones OT (2010) Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neurosci Res 67(3):245\u2013249","journal-title":"Neurosci Res"},{"issue":"2","key":"9539_CR2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2005.10.069","volume":"395","author":"A Alachkar","year":"2006","unstructured":"Alachkar A, Brotchie J, Jones OT (2006) alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata. Neurosci Lett 395(2):138\u2013142","journal-title":"Neurosci Lett"},{"issue":"2","key":"9539_CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.taap.2009.07.010","volume":"240","author":"M Alam","year":"2009","unstructured":"Alam M, Danysz W, Schmidt WJ, Dekundy A (2009) Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol Appl Pharmacol 240(2):198\u2013207","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"9539_CR4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(94)91782-5","volume":"650","author":"C Aoki","year":"1994","unstructured":"Aoki C, Go CG, Venkatesan C, Kurose H (1994) Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity. Brain Res 650(2):181\u2013204","journal-title":"Brain Res"},{"issue":"2","key":"9539_CR5","first-page":"80","volume":"35","author":"E Bertrand","year":"1997","unstructured":"Bertrand E, Lechowicz W, Szpak GM, Dymecki J (1997) Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson\u2019s disease. Folia Neuropathol 35(2):80\u201386","journal-title":"Folia Neuropathol"},{"issue":"3","key":"9539_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/14740338.3.3.209","volume":"3","author":"JL Bosboom","year":"2004","unstructured":"Bosboom JL, Wolters E (2004) Psychotic symptoms in Parkinson\u2019s disease: pathophysiology and management. Expert Opin Drug Saf 3(3):209\u2013220","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"9539_CR7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0022-5347(25)00203-4","volume":"241","author":"CL Boyajian","year":"1987","unstructured":"Boyajian CL, Loughlin SE, Leslie FM (1987) Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. J Pharmacol Exp Ther 241(3):1079\u20131091","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"9539_CR8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","volume":"20","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20(8):919\u2013931","journal-title":"Mov Disord"},{"issue":"1","key":"9539_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuroscience.2008.12.026","volume":"159","author":"K Buck","year":"2009","unstructured":"Buck K, Ferger B (2009) Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience 159(1):16\u201320","journal-title":"Neuroscience"},{"issue":"6","key":"9539_CR10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002826-200311000-00008","volume":"26","author":"C Colosimo","year":"2003","unstructured":"Colosimo C, Craus A (2003) Noradrenergic drugs for levodopa-induced dyskinesia. Clin Neuropharmacol 26(6):299\u2013305","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"9539_CR11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mds.870050203","volume":"5","author":"AR Crossman","year":"1990","unstructured":"Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson\u2019s disease: implications for future strategies in treatment. Mov Disord 5(2):100\u2013108","journal-title":"Mov Disord"},{"issue":"1","key":"9539_CR12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389","journal-title":"Behav Brain Res"},{"issue":"1","key":"9539_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00213-002-1381-y","volume":"167","author":"P Devoto","year":"2003","unstructured":"Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL (2003) Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacol Berl 167(1):79\u201384","journal-title":"Psychopharmacol Berl"},{"key":"9539_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2202-6-31","volume":"6","author":"P Devoto","year":"2005","unstructured":"Devoto P, Flore G, Saba P, Fa M, Gessa GL (2005) Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus. BMC Neurosci 6:31","journal-title":"BMC Neurosci"},{"issue":"7","key":"9539_CR15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/jnr.21611","volume":"86","author":"P Devoto","year":"2008","unstructured":"Devoto P, Flore G, Saba P, Castelli MP, Piras AP, Luesu W, Viaggi MC, Ennas MG, Gessa GL (2008) 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. J Neurosci Res 86(7):1647\u20131658","journal-title":"J Neurosci Res"},{"issue":"4","key":"9539_CR16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0091-3057(76)90107-6","volume":"5","author":"A Dolphin","year":"1976","unstructured":"Dolphin A, Jenner P, Marsden CD (1976) Noradrenaline synthesis from l-DOPA in rodents and its relationship to motor activity. Pharmacol Biochem Behav 5(4):431\u2013439","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"9539_CR17","first-page":"142","volume":"547","author":"M Filion","year":"1991","unstructured":"Filion M, Tremblay L (1991) Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547(1):142\u2013151","journal-title":"Brain Res"},{"key":"9539_CR18","doi-asserted-by":"crossref","unstructured":"Flordellis CS, Castellano M, Franco R, Zannis VI, Gavras H (1990) Expression of multiple alpha 2-adrenergic receptor messenger RNA species in rat tissues. Hypertension 15(6 Pt 2):881\u2013887","DOI":"10.1161\/01.HYP.15.6.881"},{"issue":"22","key":"9539_CR19","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2174\/092986707781745550","volume":"14","author":"F Fornai","year":"2007","unstructured":"Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A (2007) Noradrenaline in Parkinson\u2019s disease: from disease progression to current therapeutics. Curr Med Chem 14(22):2330\u20132334","journal-title":"Curr Med Chem"},{"issue":"4","key":"9539_CR20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","volume":"16","author":"SH Fox","year":"2001","unstructured":"Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16(4):642\u2013650","journal-title":"Mov Disord"},{"issue":"7","key":"9539_CR21","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.clinph.2008.03.017","volume":"119","author":"A Galvan","year":"2008","unstructured":"Galvan A, Wichmann T (2008) Pathophysiology of parkinsonism. Clin Neurophysiol 119(7):1459\u20131474","journal-title":"Clin Neurophysiol"},{"issue":"6","key":"9539_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","volume":"24","author":"M Gesi","year":"2000","unstructured":"Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F (2000) The role of the locus coeruleus in the development of Parkinson\u2019s disease. Neurosci Biobehav Rev 24(6):655\u2013668","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"9539_CR23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1586\/14737175.9.2.279","volume":"9","author":"YA Grimbergen","year":"2009","unstructured":"Grimbergen YA, Langston JW, Roos RA, Bloem BR (2009) Postural instability in Parkinson\u2019s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 9(2):279\u2013290","journal-title":"Expert Rev Neurother"},{"key":"9539_CR24","doi-asserted-by":"crossref","unstructured":"Grondin R, Hadj TA, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361(2):181\u2013186","DOI":"10.1007\/s002109900167"},{"issue":"5","key":"9539_CR25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1124\/mol.108.048033","volume":"74","author":"BP Guiard","year":"2008","unstructured":"Guiard BP, El Mansari M, Blier P (2008a) Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 74(5):1463\u20131475","journal-title":"Mol Pharmacol"},{"issue":"5","key":"9539_CR26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1017\/S1461145707008383","volume":"11","author":"BP Guiard","year":"2008","unstructured":"Guiard BP, El Mansari M, Merali Z, Blier P (2008b) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11(5):625\u2013639","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"9539_CR27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00210-003-0827-z","volume":"368","author":"A Haapalinna","year":"2003","unstructured":"Haapalinna A, Leino T, Heinonen E (2003) The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedebergs Arch Pharmacol 368(5):342\u2013351","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"9539_CR28","first-page":"53","volume":"78","author":"B Henry","year":"1998","unstructured":"Henry B, Crossman AR, Brotchie JM (1998) Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of l-dopa-induced dyskinesia. Adv Neurol 78:53\u201361","journal-title":"Adv Neurol"},{"issue":"5","key":"9539_CR29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","volume":"14","author":"B Henry","year":"1999","unstructured":"Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord 14(5):744\u2013753","journal-title":"Mov Disord"},{"issue":"7","key":"9539_CR30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.bjp.0702943","volume":"128","author":"MP Hill","year":"1999","unstructured":"Hill MP, Brotchie JM (1999) The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br J Pharmacol 128(7):1577\u20131585","journal-title":"Br J Pharmacol"},{"issue":"4","key":"9539_CR31","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0306-4522(99)00260-2","volume":"93","author":"M Holmberg","year":"1999","unstructured":"Holmberg M, Scheinin M, Kurose H, Miettinen R (1999) Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 93(4):1323\u20131333","journal-title":"Neuroscience"},{"key":"9539_CR32","first-page":"19","volume":"45","author":"O Hornykiewicz","year":"1987","unstructured":"Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson\u2019s disease. Adv Neurol 45:19\u201334","journal-title":"Adv Neurol"},{"issue":"1\u20132","key":"9539_CR33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","volume":"626","author":"JL Hudson","year":"1993","unstructured":"Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626(1\u20132):167\u2013174","journal-title":"Brain Res"},{"issue":"1","key":"9539_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(77)90377-8","volume":"127","author":"BE Jones","year":"1977","unstructured":"Jones BE, Halaris AE, McIlhany M, Moore RY (1977) Ascending projections of the locus coeruleus in the rat. I. Axonal transport in central noradrenaline neurons. Brain Res 127(1):1\u201321","journal-title":"Brain Res"},{"key":"9539_CR35","unstructured":"Lanier SM, Downing S, Duzic E, Homcy CJ (1991) Isolation of rat genomic clones encoding subtypes of the alpha 2-adrenergic receptor. Identification of a unique receptor subtype. J Biol Chem 266(16):10470\u201310478"},{"issue":"1\u20132","key":"9539_CR36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(98)00266-2","volume":"795","author":"A Lee","year":"1998","unstructured":"Lee A, Rosin DL, Van Bockstaele EJ (1998) alpha2A-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals. Brain Res 795(1\u20132):157\u2013169","journal-title":"Brain Res"},{"issue":"Pt 3","key":"9539_CR37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/brain\/115.3.809","volume":"115","author":"IJ Mitchell","year":"1992","unstructured":"Mitchell IJ, Boyce S, Sambrook MA, Crossman AR (1992) A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 115(Pt 3):809\u2013824","journal-title":"Brain"},{"key":"9539_CR38","doi-asserted-by":"crossref","unstructured":"Nagatsu T, Sawada M (2007) Biochemistry of postmortem brains in Parkinson\u2019s disease: historical overview and future prospects. J Neural Transm Suppl (72): 113\u201320","DOI":"10.1007\/978-3-211-73574-9_14"},{"issue":"4","key":"9539_CR39","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cne.903280409","volume":"328","author":"AP Nicholas","year":"1993","unstructured":"Nicholas AP, Pieribone V, Hokfelt T (1993) Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 328(4):575\u2013594","journal-title":"J Comp Neurol"},{"issue":"2","key":"9539_CR40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0304-3940(91)90941-L","volume":"123","author":"K Nishi","year":"1991","unstructured":"Nishi K, Kondo T, Narabayashi H (1991) Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-dopa. Neurosci Lett 123(2):244\u2013247","journal-title":"Neurosci Lett"},{"issue":"2","key":"9539_CR41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/PL00005036","volume":"356","author":"W Norenberg","year":"1997","unstructured":"Norenberg W, Schoffel E, Szabo B, Starke K (1997) Subtype determination of soma-dendritic alpha2-autoreceptors in slices of rat locus coeruleus. Naunyn Schmiedebergs Arch Pharmacol 356(2):159\u2013165","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"9539_CR42","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"1986","unstructured":"Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Sydney","edition":"2"},{"issue":"3","key":"9539_CR43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0014-2999(70)90007-5","volume":"11","author":"T Persson","year":"1970","unstructured":"Persson T, Waldeck B (1970) Further studies on the possible interaction between dopamine and noradrenaline containing neurons in the brain. Eur J Pharmacol 11(3):315\u2013320","journal-title":"Eur J Pharmacol"},{"issue":"Pt 6","key":"9539_CR44","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314\u20131322","journal-title":"Brain"},{"issue":"7","key":"9539_CR45","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.bjp.0703963","volume":"132","author":"C Ribas","year":"2001","unstructured":"Ribas C, Miralles A, Busquets X, Garcia-Sevilla JA (2001) Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA. Br J Pharmacol 132(7):1467\u20131476","journal-title":"Br J Pharmacol"},{"issue":"2","key":"9539_CR46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2007.01.036","volume":"74","author":"KS Rommelfanger","year":"2007","unstructured":"Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson\u2019s disease. Biochem Pharmacol 74(2):177\u2013190","journal-title":"Biochem Pharmacol"},{"issue":"34","key":"9539_CR47","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1073\/pnas.0702753104","volume":"104","author":"KS Rommelfanger","year":"2007","unstructured":"Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 104(34):13804\u201313809","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"9539_CR48","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","volume":"18","author":"JM Savola","year":"2003","unstructured":"Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord 18(8):872\u2013883","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"9539_CR49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0169-328X(94)90386-7","volume":"21","author":"M Scheinin","year":"1994","unstructured":"Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, Fremeau RT Jr (1994) Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21(1\u20132):133\u2013149","journal-title":"Brain Res Mol Brain Res"},{"issue":"2","key":"9539_CR50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1006\/exnr.2001.7649","volume":"169","author":"MA Silverdale","year":"2001","unstructured":"Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson\u2019s disease. Exp Neurol 169(2):400\u2013406","journal-title":"Exp Neurol"},{"issue":"6","key":"9539_CR51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00210-004-0929-2","volume":"369","author":"J Srinivasan","year":"2004","unstructured":"Srinivasan J, Schmidt WJ (2004a) The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? Naunyn Schmiedebergs Arch Pharmacol 369(6):629\u2013638","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1\u20132","key":"9539_CR52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2003.08.016","volume":"151","author":"J Srinivasan","year":"2004","unstructured":"Srinivasan J, Schmidt WJ (2004b) Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson\u2019s disease. Behav Brain Res 151(1\u20132):191\u2013199","journal-title":"Behav Brain Res"},{"issue":"1","key":"9539_CR53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0165-0173(84)90030-4","volume":"319","author":"JR Unnerstall","year":"1984","unstructured":"Unnerstall JR, Kopajtic TA, Kuhar MJ (1984) Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res 319(1):69\u2013101","journal-title":"Brain Res"},{"issue":"1\u20132","key":"9539_CR54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0006-8993(97)00860-3","volume":"770","author":"S Uhlen","year":"1997","unstructured":"Uhlen S, Lindblom J, Johnson A, Wikberg JE (1997) Autoradiographic studies of central alpha 2A- and alpha 2C-adrenoceptors in the rat using [3H]MK912 and subtype-selective drugs. Brain Res 770(1\u20132):261\u2013266","journal-title":"Brain Res"},{"issue":"1","key":"9539_CR55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12264-009-1023-z","volume":"25","author":"T Wang","year":"2009","unstructured":"Wang T, Zhang QJ, Liu J, Wu ZH, Wang S (2009) Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism. Neurosci Bull 25(1):15\u201320","journal-title":"Neurosci Bull"},{"issue":"1\u20133","key":"9539_CR56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-2999(03)01324-4","volume":"462","author":"L Yavich","year":"2003","unstructured":"Yavich L, Sirvio J, Haapalinna A, Ylinen A, Mannisto PT (2003) Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 462(1\u20133):83\u201389","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"9539_CR57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0169-328X(91)90064-5","volume":"10","author":"DW Zeng","year":"1991","unstructured":"Zeng DW, Lynch KR (1991) Distribution of alpha 2-adrenergic receptor mRNAs in the rat CNS. Brain Res Mol Brain Res 10(3):219\u2013225","journal-title":"Brain Res Mol Brain Res"},{"issue":"1\u20132","key":"9539_CR58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0169-328X(03)00026-3","volume":"112","author":"W Zhang","year":"2003","unstructured":"Zhang W, Ordway GA (2003) The alpha (2C)-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res 112(1\u20132):24\u201332","journal-title":"Brain Res Mol Brain Res"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-011-9539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-011-9539-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-011-9539-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:47:47Z","timestamp":1741182467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-011-9539-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,12]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["9539"],"URL":"https:\/\/doi.org\/10.1007\/s12031-011-9539-x","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,12]]}}}